JP2820239B2 - 制御放出パウダー及びその製法 - Google Patents

制御放出パウダー及びその製法

Info

Publication number
JP2820239B2
JP2820239B2 JP60242585A JP24258585A JP2820239B2 JP 2820239 B2 JP2820239 B2 JP 2820239B2 JP 60242585 A JP60242585 A JP 60242585A JP 24258585 A JP24258585 A JP 24258585A JP 2820239 B2 JP2820239 B2 JP 2820239B2
Authority
JP
Japan
Prior art keywords
theophylline
polymer
controlled release
powder
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60242585A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61109711A (ja
Inventor
ジエームズ ゲイガン エドワーズ
テイ スパークス ランドル
Original Assignee
エラン コーポレーション ピー エル シー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン コーポレーション ピー エル シー filed Critical エラン コーポレーション ピー エル シー
Publication of JPS61109711A publication Critical patent/JPS61109711A/ja
Application granted granted Critical
Publication of JP2820239B2 publication Critical patent/JP2820239B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/18—Chewing gum characterised by shape, structure or physical form, e.g. aerated products
    • A23G4/20—Composite products, e.g. centre-filled, multi-layer, laminated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
JP60242585A 1984-10-30 1985-10-29 制御放出パウダー及びその製法 Expired - Lifetime JP2820239B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2788/84 1984-10-30
IE278884A IE58110B1 (en) 1984-10-30 1984-10-30 Controlled release powder and process for its preparation

Publications (2)

Publication Number Publication Date
JPS61109711A JPS61109711A (ja) 1986-05-28
JP2820239B2 true JP2820239B2 (ja) 1998-11-05

Family

ID=11036490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60242585A Expired - Lifetime JP2820239B2 (ja) 1984-10-30 1985-10-29 制御放出パウダー及びその製法

Country Status (16)

Country Link
US (3) US4952402A (cg-RX-API-DMAC7.html)
JP (1) JP2820239B2 (cg-RX-API-DMAC7.html)
AU (1) AU579415B2 (cg-RX-API-DMAC7.html)
BE (2) BE903541Q (cg-RX-API-DMAC7.html)
CA (1) CA1268051A (cg-RX-API-DMAC7.html)
CH (1) CH669728A5 (cg-RX-API-DMAC7.html)
DE (1) DE3538429C2 (cg-RX-API-DMAC7.html)
DK (1) DK175329B1 (cg-RX-API-DMAC7.html)
FR (1) FR2572282B1 (cg-RX-API-DMAC7.html)
GB (1) GB2166651B (cg-RX-API-DMAC7.html)
HK (1) HK44091A (cg-RX-API-DMAC7.html)
IE (1) IE58110B1 (cg-RX-API-DMAC7.html)
IT (1) IT1185831B (cg-RX-API-DMAC7.html)
NL (1) NL193582C (cg-RX-API-DMAC7.html)
SE (1) SE8505099L (cg-RX-API-DMAC7.html)
ZA (1) ZA858300B (cg-RX-API-DMAC7.html)

Families Citing this family (1358)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
IT1178511B (it) * 1984-09-14 1987-09-09 Pharmatec Spa Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
CH669523A5 (cg-RX-API-DMAC7.html) * 1986-06-25 1989-03-31 Mepha Ag
DE3784594T2 (de) * 1986-08-11 1994-01-05 Innovata Biomed Ltd Mikrokapseln enthaltende pharmazeutische Zusammensetzungen.
US5030632A (en) * 1986-09-23 1991-07-09 Sandoz Pharm. Corp. Low dose temazepam
US5629310A (en) * 1986-09-23 1997-05-13 Sterling; William R. Low dose temazepam
US5211954A (en) * 1986-09-23 1993-05-18 Sandoz Ltd. Low dose temazepam
GB8624628D0 (en) * 1986-10-14 1986-11-19 Scras Soluble/splitable tablets
HU205861B (en) * 1986-12-19 1992-07-28 Sandoz Ag Process for producing hydrosole of pharmaceutically effective material
SE8605515D0 (sv) * 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
CH673395A5 (cg-RX-API-DMAC7.html) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5283067A (en) * 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US4975270A (en) * 1987-04-21 1990-12-04 Nabisco Brands, Inc. Elastomer encased active ingredients
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
EP0297866A3 (en) * 1987-07-01 1989-12-13 The Boots Company PLC Therapeutic agents
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
NZ226822A (en) * 1987-11-16 1990-03-27 Mcneil Consumer Prod Chewable medicament tablet containing means for taste masking
US5095054A (en) * 1988-02-03 1992-03-10 Warner-Lambert Company Polymer compositions containing destructurized starch
ZA892859B (en) * 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
DE3834944A1 (de) * 1988-10-13 1990-04-26 Ars Japan Kk Arzneimittelfreigabevorrichtung
US5840293A (en) * 1988-11-16 1998-11-24 Advanced Polymer Systems, Inc. Ionic beads for controlled release and adsorption
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5139787A (en) * 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5209923A (en) * 1989-05-30 1993-05-11 Moleculon, Inc. Sunscreen composition
US5206019A (en) * 1989-05-30 1993-04-27 Moleculon, Inc. Soap compositions containing liquid-loaded powders
US5209932A (en) * 1989-05-30 1993-05-11 Moleculon, Inc. Foot care compositions
US5290570A (en) * 1989-05-30 1994-03-01 Purepac, Inc. Lotions containing liquid-loaded powder
US5206022A (en) * 1989-05-30 1993-04-27 Moleculon, Inc. Insect repellent compositions
US5223267A (en) * 1989-05-30 1993-06-29 Purepac, Inc. Analgesic compositions
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
FR2649888B1 (fr) * 1989-07-18 1994-08-26 Exsymol Sa Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques
CA2063141C (en) * 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
NZ234587A (en) * 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
ES2084712T3 (es) * 1989-11-06 1996-05-16 Alkermes Inc Metodo para producir microesferas proteicas.
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
ES2081384T3 (es) * 1990-04-25 1996-03-01 Hoechst Ag Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.
FR2661683A1 (fr) * 1990-05-02 1991-11-08 Rhone Poulenc Chimie Systeme matriciel de liberation controlee comportant un principe actif hydrosoluble disperse dans une matrice constituee d'un copolymere silicone thermoplastique.
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5260072A (en) * 1990-08-30 1993-11-09 Mcneil-Ppc, Inc. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
FR2669222B1 (fr) 1990-11-15 1995-03-03 Oreal Compositions cosmetiques sous forme de poudres coulees comprenant des microspheres creuses, et leur preparation.
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
US5562914A (en) * 1990-12-06 1996-10-08 Zeneca Inc. Impregnated porous granules and a polyurethane matrix held within the pores thereof and holding a liquid material for controlled release of liquid material and process therefor
GB9026682D0 (en) * 1990-12-07 1991-01-23 Walker Bryan J Lightweight aggregate
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5116627A (en) * 1991-03-07 1992-05-26 International Flavors & Fragrances Inc. Chewing gum containing compositions for controlled release of flavor bearing substances and process for producing same
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
DE69233130T2 (de) * 1991-05-28 2005-06-02 Mcneil-Ppc, Inc. Kaubare zusammensetzung zur arzneimittelfreisetzung
DE4120918A1 (de) * 1991-06-25 1993-01-07 Basf Ag Pulverfoermige praeparate aus einer wasserunloeslichen kernsubstanz und einer schutzhuelle
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
EP0521388B1 (de) * 1991-07-01 1995-05-10 Gerhard Dr. Gergely Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
DE4122217C2 (de) * 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
ES2034891B1 (es) * 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
US5300305A (en) * 1991-09-12 1994-04-05 The Procter & Gamble Company Breath protection microcapsules
FR2681248B1 (fr) * 1991-09-13 1995-04-28 Oreal Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau.
FI942765A0 (fi) * 1991-12-11 1994-06-10 Procter & Gamble Setyylipyridiniumkloridi ja domifeenibromidi orgaanisessa liottimessa
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2127877A1 (en) * 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
AU3941493A (en) * 1992-03-30 1993-11-08 Alza Corporation Viscous suspensions of controlled-release drug particles
US5571525A (en) * 1992-03-30 1996-11-05 Alza Corporation Erosion rate modifier for use in bioerodible drug delivery devices and method of use
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
NZ252433A (en) * 1992-04-30 1996-07-26 Schering Corp Preparation of a dry hydrated cephalosporin powder formulation which is resistant to air oxidation and dehydration by mixing the drug with dry excipients and filling into a sealable storage container
EP0572731A1 (en) * 1992-06-01 1993-12-08 The Procter & Gamble Company Chewable preparation containing a decongestant
US5560921A (en) * 1992-06-01 1996-10-01 The Procter & Gamble Company Chewable decongestant compositions
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
EP0595030A3 (en) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Multi-core microspheres with delayed drug delivery and process for their manufacture.
EP0625069B1 (de) * 1992-10-26 1998-12-30 Schwarz Pharma Ag Verfahren zur herstellung von mikrokapseln
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
DK0669128T3 (da) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
US5354553A (en) * 1992-12-08 1994-10-11 Church & Dwight Co., Inc Antiperspirant-deodorant cosmetic stick products
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
CZ286051B6 (cs) * 1993-02-26 1999-12-15 The Procter & Gamble Company Farmaceutický prostředek a způsob jeho použití pro dasažení projímavého účinku
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5415877A (en) * 1993-04-23 1995-05-16 Church & Dwight Co., Inc. Bicarbonate fungicide product with a combination of surfactant ingredients
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5520924A (en) * 1993-07-09 1996-05-28 Mizu Systems Corporation Methods and articles for administering drug to the oral cavity
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
GB2281861B (en) * 1993-09-21 1997-08-20 Johnson & Johnson Medical Bioabsorbable wound implant materials containing microspheres
SK282231B6 (sk) 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. Farmaceutický prostriedok na liečenie psychotických porúch
US5516524A (en) * 1993-12-20 1996-05-14 The Procter & Gamble Company Laxative compositions containing bulk fiber
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US7077822B1 (en) * 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
CZ295827B6 (cs) * 1994-03-07 2005-11-16 Nektar Therapeutics Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments
NL9401703A (nl) * 1994-10-14 1996-05-01 Rijksuniversiteit Kauwgom.
US6555098B1 (en) 1994-12-09 2003-04-29 Church & Dwight Co., Inc. Cosmetic deodorant products containing encapsulated bicarbonate and fragrance ingredients
CN1132070A (zh) * 1994-12-21 1996-10-02 麦克尼尔-Ppc公司 药用的水悬浮液制剂
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5686107A (en) * 1995-01-30 1997-11-11 Fmc Corporation Chewable pharmaceutical tablets
US6165988A (en) * 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
WO1996027288A1 (en) * 1995-03-08 1996-09-12 Church & Dwight Company, Inc. Encapsulated bicarbonate-containing agrochemical compositions
DE19516787A1 (de) * 1995-05-08 1996-11-14 Bayer Ag Gegen Gamma-Strahlung stabilisierte (Co)Polycarbonate
TW493991B (en) * 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
WO1997013503A1 (en) * 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
CA2193714A1 (en) * 1995-12-21 1997-06-22 Wilhelm Rademacher Encapsulated plant growth regulator formulations and applications
US5837653A (en) * 1995-12-21 1998-11-17 Basf Corporation Encapsulated plant growth regulator formulations
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
AU751497B2 (en) * 1996-04-23 2002-08-15 Mayne Pharma International Pty Ltd Taste masked pharmaceutical compositions
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
AU5571598A (en) * 1996-11-22 1998-06-10 Rhone-Poulenc Agrochimie Novel solid compositions based on an insoluble cellulose derivative and a 1-arylpyrazole derivative
FR2764775A1 (fr) * 1997-06-20 1998-12-24 Rhone Poulenc Agrochimie Nouvelles compositions a base de 1-aryl-pyrazole
WO1998021960A1 (fr) * 1996-11-22 1998-05-28 Rhone-Poulenc Agrochimie Nouvelles compositions solides a base de derive cellulosique insoluble et de derive de 1-aryl-pyrazole
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
DE19726195A1 (de) 1997-06-20 1998-12-24 Bayer Ag Verwendung von Saccharin zur Stabilisierung von thermoplastischen, aromatischen Polycarbonaten
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JP2001518490A (ja) * 1997-10-03 2001-10-16 エラン コーポレーシヨン ピーエルシー 味遮蔽された製剤
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FI105074B (fi) * 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
NZ535135A (en) * 1998-06-15 2006-04-28 Sepracor Inc Use of optically pure (+)-norcisapride for treating bulimia and other disorders
TR200103762T2 (tr) 1998-06-15 2002-05-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı.
ATE320816T1 (de) * 1998-07-08 2006-04-15 Kirin Amgen Inc Pulverförmiges präparat zur anwendung auf schleimhäuten welches ein polymeres arzneimittel enthält
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
GB9816724D0 (en) * 1998-08-01 1998-09-30 Boots Co Plc Therapeutic agents
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6254891B1 (en) 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
WO2000016742A1 (en) * 1998-09-24 2000-03-30 The Procter & Gamble Company Chewable compositions containing dextromethorphan
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
DK1126826T6 (en) 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP3141107B2 (ja) * 1998-11-16 2001-03-05 工業技術院長 ヒト由来ブラディオン蛋白質、それをコードするｄｎａ及びそれらの使用
US6902898B2 (en) * 1998-11-16 2005-06-07 National Institute Of Advanced Industrial Science And Technology Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CA2371822A1 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
EP1905757A1 (en) * 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
US6261600B1 (en) 1999-04-30 2001-07-17 Drugtech Corporation Folic acid supplement
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20030083383A1 (en) * 1999-08-16 2003-05-01 Spallholz Julian E. Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
AU762934B2 (en) * 1999-09-03 2003-07-10 Allergan Sales, Llc Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6705757B2 (en) * 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
CA2404152C (en) * 2000-03-31 2008-08-05 Celgene Corporation Inhibition of cyclooxygenase-2 activity
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CA2409093C (en) 2000-05-16 2009-07-21 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2001091730A1 (en) 2000-05-31 2001-12-06 Drugtech Corporation Mineral supplement
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
CN1440282A (zh) * 2000-07-06 2003-09-03 德尔西斯药品公司 改善的甲状腺激素制剂
JP2002037727A (ja) * 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
WO2002009669A2 (en) * 2000-08-01 2002-02-07 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution and particles made thereby
EP1309360B1 (en) 2000-08-15 2006-04-19 SurModics, Inc. Medicament incorporation matrix
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
HU230875B1 (hu) 2000-10-30 2018-11-29 Euro-Celtique S.A. Szabályozott hatóanyag-leadású hidrokodon készítmények
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
PT1353672E (pt) * 2000-11-30 2008-01-11 Childrens Medical Center Síntese da 4-amino talidomida enantiómeros
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
BR0207157A (pt) * 2001-02-12 2004-02-17 Wyeth Corp Sal de succinato de o-desmetil-venlafaxina
US6759064B2 (en) 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
US7192612B2 (en) * 2001-02-22 2007-03-20 Purdue Research Foundation Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
JP2004524410A (ja) * 2001-03-23 2004-08-12 ガムリンク エー／エス チューインガム用の分解可能な樹脂置換体
ES2554389T3 (es) * 2001-03-23 2015-12-18 Gumlink A/S Goma de mascar biodegradable y método para manufacturar tal goma de mascar
EA005626B1 (ru) * 2001-03-23 2005-04-28 Гумлинк А/С Покрытая оболочкой разлагающаяся жевательная резинка с улучшенным сроком хранения и способ ее получения
ES2295328T3 (es) * 2001-03-23 2008-04-16 Gumlink A/S Procedimiento en una etapa para la preparacion de goma de mascar.
US20040156949A1 (en) * 2001-03-23 2004-08-12 Lone Andersen Degradable elastomers for chewing gum base
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2003003809A2 (en) * 2001-07-05 2003-01-16 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
US20030039687A1 (en) * 2001-08-01 2003-02-27 Michael Corbo Taste masking composition
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
JP4837892B2 (ja) * 2001-11-01 2011-12-14 ネクター セラピューティクス 粉末バッチを製造する方法
IL162269A0 (en) 2001-12-05 2005-11-20 Baylor College Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
DE10163142A1 (de) * 2001-12-20 2003-07-10 Henkel Kgaa Polymere Duftkapseln und ihre Herstellung
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
WO2003059319A1 (en) * 2002-01-14 2003-07-24 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
JP4583760B2 (ja) 2002-02-01 2010-11-17 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用な治療薬
ES2343405T3 (es) 2002-02-04 2010-07-30 Elan Pharma International Ltd. Composiciones nanoparticuladas que tienen lisozima como un estabilizador de superficie.
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
EP1499295A4 (en) * 2002-04-05 2006-04-05 Penwest Pharmaceuticals Co EXTENDED RELEASE METOPROLOL FORMULATIONS
MXPA04009979A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
US6958161B2 (en) 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
ATE425744T1 (de) * 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2752140A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
CN1668296A (zh) * 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003243354A1 (en) * 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
AU2003243699B2 (en) * 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
WO2004004478A1 (en) * 2002-07-02 2004-01-15 Gumlink A/S Compressed chewing gum tablet ii
US20050175733A1 (en) * 2002-07-02 2005-08-11 Bitten Thorengaard Compressed resin moderated chewing gum
AU2002320960B2 (en) * 2002-07-02 2008-09-11 Gumlink A/S Compressed chewing gum
US6673792B1 (en) * 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
GB0216413D0 (en) * 2002-07-15 2002-08-21 Nestle Sa Tabletted chewing gum sweet
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
EP1545468A4 (en) * 2002-09-20 2007-06-20 Alpharma Inc SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
AU2002342578B2 (en) * 2002-09-24 2008-05-15 Gumlink A/S Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer
BR0215889A (pt) * 2002-09-24 2005-07-26 Gumlink As Goma de mascar de baixa umidade
BR0215885A (pt) * 2002-09-24 2005-07-26 Gumlink As Polìmero degradável de goma de mascar
AU2002340774B2 (en) * 2002-09-24 2008-10-02 Gumlink A/S Chewing gum comprising at least two different biodegradable polymers
MXPA05002962A (es) * 2002-09-24 2005-08-16 Gumlink As Goma de mascar que tiene una liberacion mejorada de los ingredientes de la goma de mascar.
DE60313478T2 (de) 2002-09-25 2008-01-03 Euro-Celtique S.A. N-substituierte hydromorphone und ihre anwendung
AU2003276987B2 (en) * 2002-09-27 2009-07-30 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
AU2003276988B2 (en) * 2002-09-27 2009-11-05 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2003279213B2 (en) * 2002-10-11 2008-12-18 Cognitive Clarity Inc. Isolation, purification and synthesis of procyanidin B2 and uses thereof
BR0315316A (pt) * 2002-10-15 2005-08-16 Celgene Corp Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ540383A (en) 2002-11-06 2008-03-28 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of chronic uveitis
JP2006507324A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
BR0316259A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
EP1569599A2 (en) * 2002-11-18 2005-09-07 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
CA2508722A1 (en) * 2002-12-11 2004-06-24 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20060051455A1 (en) * 2003-02-04 2006-03-09 Lone Andersen Compressed chewing gum tablet
DK1589825T4 (da) * 2003-02-04 2012-11-05 Gumlink As Komprimeret tyggegummitablet
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
EP1608339B8 (en) 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide
CA2542520A1 (en) * 2003-03-13 2004-09-23 Altair Nanomaterials, Inc. Manufacturing of photocatalytic, antibacterial, selfcleaning and optically non-interfering surfaces on tiles and glazed ceramic products
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
EP2207036B1 (en) * 2003-03-24 2012-12-12 Gen-Probe Transplant Diagnostics, Inc. Methods for determining the negative control value for multi-analyte assays
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
ES2535045T3 (es) * 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
EP3889142B1 (en) 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
EP1474993B1 (en) * 2003-05-06 2008-08-20 Gumlink A/S A method for producing chewing gum granules and compressed gum products, and a chewing gum granulating system
EP1474995B1 (en) * 2003-05-06 2012-11-14 Gumlink A/S A method for producing chewing gum granules, a gum composition extruder and granulating system, and a chewing gum product
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US7186863B2 (en) * 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
DE10326899A1 (de) 2003-06-14 2004-12-30 Beiersdorf Ag Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
US7605194B2 (en) 2003-06-24 2009-10-20 Ppg Industries Ohio, Inc. Aqueous dispersions of polymer-enclosed particles, related coating compositions and coated substrates
US20080112909A1 (en) * 2003-06-24 2008-05-15 Ppg Industries Ohio, Inc. Compositions for providing color to animate objects and related methods
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ES2322707T3 (es) * 2003-07-03 2009-06-25 Euro-Celtique S.A. Derivados de 2-piridina alquino utiles para tratar el dolor.
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
DK1651232T3 (da) 2003-07-23 2011-02-28 Synta Pharmaceuticals Corp Forbindelser mod inflammation og immunrelaterede anvendelser
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
SI1648878T1 (sl) * 2003-07-24 2009-10-31 Euro Celtique Sa Piperidinske spojine in farmacevtski sestavki, ki jih vsebujejo
MXPA06000940A (es) 2003-07-24 2006-03-30 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento de dolor.
CN103040773A (zh) * 2003-07-25 2013-04-17 沃纳奇尔科特有限责任公司 多西环素金属络合物固体剂型
HRP20100229T1 (hr) 2003-08-01 2010-05-31 Euro-Celtique S.A. Terapeutski agensi korisni za liječenje boli
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050232992A1 (en) * 2003-09-03 2005-10-20 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2004276252B2 (en) * 2003-09-22 2007-11-22 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4634385B2 (ja) * 2003-09-22 2011-02-16 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用なフェニル−カルボキサミド化合物
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
US20070208057A1 (en) * 2003-11-06 2007-09-06 Zeldis Jerome B Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
EP1692128A1 (en) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Indazole compounds and methods of use thereof as protein kinase inhibitors
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8591974B2 (en) * 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8389032B2 (en) * 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
CN1925752A (zh) * 2003-12-30 2007-03-07 古木林科有限公司 压缩生物可降解口香糖
JP2007525146A (ja) * 2003-12-30 2007-09-06 ガムリンク エー／エス 生分解性ポリマーを含み且つ分解性を促進させたチューインガム
NZ548169A (en) * 2003-12-30 2009-04-30 Euro Celtique Sa Piperazines useful for treating pain
ATE500821T1 (de) 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
DE602004031462D1 (de) * 2003-12-31 2011-03-31 Cima Labs Inc Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
CA2556220A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
PL1720540T3 (pl) 2004-02-18 2008-11-28 Gpc Biotech Ag Satraplatyna do leczenia odpornych i opornych nowotworów
US20090246288A1 (en) * 2004-02-25 2009-10-01 Pharmaceutical Industry Technology And Development Center Taste-masking oral dosage form and method of preparing the same
TWI335227B (en) 2004-02-25 2011-01-01 Medical & Pharm Ind Tech & Dev Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
US20050202051A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical vehicle
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
DE102004013637A1 (de) * 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
CA2560221C (en) 2004-03-22 2010-12-07 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
WO2005092065A2 (en) * 2004-03-25 2005-10-06 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
FR2868426B1 (fr) * 2004-04-05 2006-06-02 Rhodia Chimie Sa Composition comprenant un polymere et un compose volatil, et son utilisation pour la liberation controlee du compose volatil
EP1744748A4 (en) * 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
US20080199422A1 (en) * 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
JP5030292B2 (ja) 2004-04-15 2012-09-19 アミリン・ファーマシューティカルズ，インコーポレイテッド ポリマーを基にした持続放出性装置
EP1755589A4 (en) * 2004-04-23 2007-11-07 Celgene Corp METHOD OF USING PDE4 MODULATORS AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
EP1600210A1 (de) * 2004-05-25 2005-11-30 Cognis IP Management GmbH Beladene Mikrosphären
ATE483455T1 (de) 2004-05-28 2010-10-15 Transform Pharmaceuticals Inc Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
WO2006007448A2 (en) * 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
ATE418328T1 (de) 2004-07-06 2009-01-15 Gumlink As Komprimierte kaugummitablette
US20060127486A1 (en) * 2004-07-13 2006-06-15 Moerck Rudi E Ceramic structures for prevention of drug diversion
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
NZ552389A (en) * 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
DK200401195A (da) * 2004-08-06 2004-08-06 Gumlink As Layered chewing gum tablet
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CZ296169B6 (cs) * 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
PT1803447E (pt) * 2004-09-09 2009-08-14 Psicofarma S A De C V Composição farmacêutica para a libertação sustentada de hidralazina e seu uso como apoio para o tratamento do cancro
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
BRPI0518062A (pt) * 2004-10-28 2008-10-28 Celgene Corp uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20080160099A1 (en) * 2004-11-10 2008-07-03 The Trustees Of Columbia University In The City Of New York Methods For Treating or Preventing a Vascular Disease
NZ555158A (en) 2004-11-18 2010-09-30 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
DK2561872T3 (en) 2004-12-17 2014-12-08 Anadys Pharmaceuticals Inc 3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
WO2006066573A1 (en) * 2004-12-22 2006-06-29 Gumlink A/S Degradable polymer for chewing gum
WO2006066572A2 (en) * 2004-12-22 2006-06-29 Gumlink A/S Biodegradable chewing gum comprising biodegradable polymer with high glass transition temperature
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
NZ556582A (en) * 2005-01-21 2010-12-24 Warner Chilcott Co Llc A tetracycline metal complex in a solid dosage form
US8518950B2 (en) * 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0607461A2 (pt) * 2005-02-14 2009-09-08 Neurogesx Inc dispositivo para liberação de agonistas de trpv1
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
CA2599951A1 (en) * 2005-03-04 2006-09-14 Altairnano, Inc. Ceramic structures for controlled release of biologically active substances
EP1700824A1 (en) * 2005-03-09 2006-09-13 Degussa AG Granules based on pyrogenically prepared silicon dioxide, method for their preparation and use thereof
US20060222690A1 (en) * 2005-03-30 2006-10-05 Bley Keith R Low-concentration capsaicin patch and methods for treating neuropathic pain
CN101189249B (zh) 2005-04-01 2013-04-17 加利福尼亚大学董事会 膦酰基-戊-2-烯-1-基核苷和类似物
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
MX2007012763A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden una cefalosporina para el tratamiento de infeccion bacteriana.
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
AU2006313443A1 (en) 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
AU2006265008A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
EP1931315B1 (en) * 2005-08-24 2013-10-16 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
US20070053983A1 (en) * 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
HK1081802A2 (en) * 2005-09-09 2006-05-19 林子深 Intelligent crossroad
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2007050631A2 (en) * 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
EP1960382A1 (en) 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20070104788A1 (en) 2005-11-10 2007-05-10 Seamus Mulligan Once-daily administration of central nervous system drugs
NZ568430A (en) * 2005-11-21 2011-02-25 Purdue Pharma Lp 4-oxadiazolyl-piperidine compounds and use thereof
AR058193A1 (es) * 2005-11-21 2008-01-23 Schering Plough Ltd Composiciones farmaceuticas
EP1971434A1 (en) * 2005-11-22 2008-09-24 Altairnano, Inc Method for manufacturing high surface area nano-porous catalyst and catalyst support structures
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
AU2007208151B2 (en) 2006-01-25 2013-04-18 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
EP1983980A4 (en) * 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
EP1998612A4 (en) 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED BIARYL COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
US7951428B2 (en) 2006-01-31 2011-05-31 Regents Of The University Of Minnesota Electrospray coating of objects
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US9248217B2 (en) 2006-01-31 2016-02-02 Nanocopocia, LLC Nanoparticle coating of surfaces
CA2640049A1 (en) 2006-01-31 2007-08-09 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
JP2009530280A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド シタクスセンタンナトリウムの配合物
AU2007225139A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US8063221B2 (en) * 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
ES2396039T3 (es) 2006-03-16 2013-02-18 Tris Pharma, Inc. Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
ES2349887T3 (es) * 2006-06-08 2011-01-12 Amgen Inc. Derivados de benzamida y usos relacionados con los mismos.
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
CA2654325A1 (en) * 2006-06-16 2007-12-21 Gumlink A/S Chewing gum comprising a hydrophobic enzyme formulation
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
CN101501039B (zh) 2006-06-22 2012-02-22 安那迪斯药品股份有限公司 吡咯并[1,2-b]哒嗪酮化合物
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AU2007293107A1 (en) * 2006-08-04 2008-03-13 Agi Therapeutics Research Limited Methods for treating at least one condition having MT1 receptor, 5HT2GB receptor, and L-type calcium channel activity
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
US8601530B2 (en) * 2006-09-19 2013-12-03 The Invention Science Fund I, Llc Evaluation systems and methods for coordinating software agents
DK2066662T3 (da) 2006-09-21 2013-01-07 Kyorin Seiyaku Kk Serinhydrolaseinhibitorer
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
SI2076268T1 (sl) 2006-10-19 2013-04-30 Genzyme Corpoartion Roskovitin za zdravljenje določenih cističnih bolezni
DE602007013440D1 (de) 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
EP2086326B1 (en) 2006-11-13 2014-01-08 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
AU2007338689A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of C3a receptor and methods of use thereof
EP2121580A2 (en) * 2006-12-26 2009-11-25 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
ATE482206T1 (de) 2007-01-16 2010-10-15 Purdue Pharma Lp Heterozyklische substituierte piperidine als orl- 1-liganden
KR101538810B1 (ko) 2007-02-09 2015-07-22 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
JP5666140B2 (ja) 2007-02-21 2015-02-12 サノヴィオン ファーマシューティカルズ インコーポレーテッド （−）−ｏ−デスメチルベンラファキシンを含む固形物およびそれらの使用
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
DK2144604T3 (da) 2007-02-28 2011-10-17 Conatus Pharmaceuticals Inc Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
EP3269706A1 (en) 2007-03-15 2018-01-17 Auspex Pharmaceuticals, Inc. Deuterated o-desmethylvenlafaxine with serotoninergic and/or norepinephrinergic activity
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
WO2008122966A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
CA2942083C (en) 2007-04-26 2019-01-29 Sigmoid Pharma Limited Manufacture of multiple minicapsules
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
CA2685121A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
IN2009KN04568A (cg-RX-API-DMAC7.html) 2007-06-01 2015-08-28 Univ Princeton
WO2009011988A2 (en) * 2007-06-05 2009-01-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
WO2009008997A2 (en) * 2007-07-06 2009-01-15 Nuon Therapeutics, Inc. Treatment of neuropathic pain
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
TWI444186B (zh) 2007-08-01 2014-07-11 Synta Pharmaceuticals Corp 用於發炎與免疫相關用途之雜環－芳基化合物
JP2010535218A (ja) 2007-08-01 2010-11-18 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のためのビニル−アリール誘導体
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
BRPI0815557A2 (pt) 2007-08-13 2015-02-18 Metabasis Therapeuticas Inc Atividaores de glicocinase
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
AU2008291823B2 (en) 2007-08-31 2012-02-23 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
CA2699151A1 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
JP5373799B2 (ja) 2007-09-12 2013-12-18 杏林製薬株式会社 Ｇｓｋ−３阻害剤としてのスピロ環式アミノキノロン
CN101952272B (zh) 2007-09-26 2014-08-27 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
US20090211576A1 (en) * 2007-10-02 2009-08-27 Timo Lehtonen Safety and abuse deterrent improved device
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
EP2959917A3 (en) 2007-10-19 2016-02-24 The Regents of The University of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2583963A1 (en) * 2008-01-08 2013-04-24 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors for the treatment of pain
CA2905541C (en) 2008-01-09 2020-02-11 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
NZ587907A (en) 2008-03-17 2012-09-28 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods of use thereof
EP2966076A1 (en) 2008-03-19 2016-01-13 ChemBridge Corporation Novel tyrosine kinase inhibitors
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
CA2718966A1 (en) * 2008-03-20 2009-09-24 Lynn Chambers Anti-inflammatory drug delivery system
WO2009120167A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
CN102177172A (zh) 2008-07-02 2011-09-07 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
RU2500678C2 (ru) * 2008-07-21 2013-12-10 Пэдью Фарма Л.П. Замещенные хиноксалинового типа мостиковые пиперидиновые соединения и их применение
HRP20140182T1 (hr) 2008-07-30 2014-04-11 Purdue Pharma Lp Analozi buprenorfina
BRPI0918004B8 (pt) 2008-08-13 2021-05-25 Metabasis Therapeutics Inc compostos antagonistas e agonistas inversos de receptores de glucagon, composição farmacêutica e uso dos compostos
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP2012504604A (ja) * 2008-10-01 2012-02-23 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用のための化合物
EP2346329B1 (en) 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
EP3354646A1 (en) 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
AU2009330355B2 (en) 2008-12-16 2016-06-30 Sunovion Pharmaceuticals Inc. Triple reuptake inhibitors and methods of their use
EP2379504A2 (en) 2008-12-22 2011-10-26 Sloan Kettering Institute For Cancer Research Coumarin-based compounds
CA2747805A1 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
US20100189845A1 (en) * 2009-01-27 2010-07-29 Frito-Lay North America Inc. Flavor Encapsulation and Method Thereof
US9504274B2 (en) * 2009-01-27 2016-11-29 Frito-Lay North America, Inc. Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
JP5749181B2 (ja) 2009-02-09 2015-07-15 スノビオン プハルマセウトイカルス インコーポレイテッド ピロリジントリプル再取込み阻害剤
EA201171035A1 (ru) 2009-02-10 2012-02-28 Селджин Корпорейшн Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
KR20190000937A (ko) 2009-02-24 2019-01-03 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
AU2010217929B2 (en) 2009-02-27 2016-07-14 Ambit Biosciences Corporation JAK kinase modulating quinazoline derivatives and methods of use thereof
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
MX2011010105A (es) 2009-03-27 2012-01-12 Pathway Therapeutics Inc Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CA2758968C (en) 2009-04-22 2018-05-29 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide ccr3 antagonists
AR078120A1 (es) 2009-04-22 2011-10-19 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas
PE20120811A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
JP2012526844A (ja) * 2009-05-15 2012-11-01 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
US20120134969A1 (en) 2009-05-25 2012-05-31 Hiroshi Handa Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
CN102803268A (zh) 2009-06-10 2012-11-28 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
WO2011005841A1 (en) 2009-07-08 2011-01-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
US20110021591A1 (en) * 2009-07-21 2011-01-27 Gordon Douglas J Phenylbutazone carrier formulation showing increased bioactivity in animals
WO2011009961A1 (en) 2009-07-24 2011-01-27 Virologik Gmbh Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
CA2773035A1 (en) 2009-09-04 2011-03-10 United Paragon Associates Inc. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
MX2012002898A (es) 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011039638A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Topical tetracycline compositions
WO2011042482A1 (en) 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011046609A2 (en) * 2009-10-15 2011-04-21 Appleton Papers Inc. Encapsulation
NZ599445A (en) 2009-10-19 2014-04-30 Synta Pharmaceuticals Corp Combination cancer therapy with hsp90 inhibitory compounds
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
EP2501382A1 (en) 2009-11-19 2012-09-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
US20110123672A1 (en) * 2009-11-23 2011-05-26 Xiaohu Xia Gum bases, chewing gums based thereupon, and methods for making the same
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011069063A2 (en) 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Multicyclic compounds and methods of use thereof
AU2010325894B2 (en) 2009-12-04 2015-07-30 Sunovion Pharmaceuticals Inc. Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181891A1 (en) 2009-12-22 2012-07-30 Celgene Corp (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
CA2785468A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
JP2013516424A (ja) 2009-12-30 2013-05-13 サイネクシス，インコーポレーテッド シクロスポリン類似体
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX349162B (es) 2010-01-04 2017-07-14 Mapi Pharma Ltd * Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
WO2011084968A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US8409628B2 (en) * 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
ES2632548T3 (es) 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
LT3202461T (lt) 2010-02-11 2019-04-25 Celgene Corporation Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai
HUE025699T2 (en) 2010-03-02 2016-04-28 Axikin Pharmaceuticals Inc Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
JP2013522236A (ja) * 2010-03-12 2013-06-13 セルジーン コーポレイション レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
US8741894B2 (en) 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
EP2556082B1 (en) 2010-04-08 2017-02-22 Emory University Substituted androst-4-ene diones
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
AU2011255438A1 (en) 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
CA2800618C (en) 2010-05-26 2018-08-28 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
CN102918031A (zh) 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
CN103038216A (zh) 2010-06-01 2013-04-10 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
WO2011153199A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011156321A1 (en) 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
ES2591355T3 (es) 2010-08-24 2016-11-28 Algiax Pharmaceuticals Gmbh Uso novedoso de leflunomida y malononitrilamidas
ES2619850T3 (es) 2010-09-01 2017-06-27 Ambit Biosciences Corporation Sales de hidrobromuro de una pirazolilaminoquinazolina
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
US8703943B2 (en) 2010-09-01 2014-04-22 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
WO2012037155A2 (en) 2010-09-13 2012-03-22 Gtx, Inc. Tyrosine kinase inhibitors
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
RS56529B1 (sr) 2010-10-18 2018-02-28 Cerenis Therapeutics Holding Sa Jedinjenja, kompozicije i postupci pogodni za mobilizaciju holesterola
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
CN103179962B (zh) 2010-10-29 2017-03-22 艾格埃克斯制药有限公司 丙二腈酰胺类似物在神经病理性疼痛中的用途
EP2638032A1 (en) 2010-11-09 2013-09-18 Synta Pharmaceuticals Corp. Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
EP2648708A2 (en) 2010-12-08 2013-10-16 Synta Pharmaceuticals Corp. Combination for breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
ES2753198T5 (es) 2010-12-16 2023-05-31 Amgen Europe Gmbh Formas farmacéuticas orales de liberación controlada de fármacos poco solubles y sus usos
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
WO2012094636A2 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013103384A1 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP2663549B1 (en) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
MX2013007959A (es) 2011-01-10 2013-12-06 Celgene Corp Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
US9566269B2 (en) 2011-01-20 2017-02-14 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
US8287903B2 (en) * 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
CN103391779A (zh) 2011-02-24 2013-11-13 辛塔医药品有限公司 使用hsp90抑制性化合物的前列腺癌治疗
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
SMT201800032T1 (it) 2011-03-11 2018-03-08 Celgene Corp Forme solide di 3-(5-ammino-2-metil-4-osso-4h-chinazolin-3-il)-piperidina-2,6-dione, e loro composizioni farmaceutiche e usi
EP2683384B1 (en) 2011-03-11 2015-12-09 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2012123406A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of imidazotriazinones
EP2685975A1 (en) 2011-03-17 2014-01-22 Algiax Pharmaceuticals GmbH Novel use of benzofuranylsulfonates
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012158271A1 (en) 2011-04-06 2012-11-22 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds as antiviral agents
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
AU2012249536B2 (en) 2011-04-28 2016-09-22 Amgen (Europe) GmbH Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012149088A1 (en) 2011-04-29 2012-11-01 Kraft Foods Global Brands Llc Encapsulated acid, method for the preparation thereof, and chewing gum comprising same
US9604978B2 (en) 2011-05-03 2017-03-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
SG195288A1 (en) 2011-06-07 2013-12-30 Anadys Pharmaceuticals Inc [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
DK2723732T3 (en) 2011-06-22 2017-04-03 Purdue Pharma Lp TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND APPLICATIONS THEREOF
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc NOVEL ANALOGUES OF FLUORO-ERGOLINE
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013006864A2 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
AU2012299177A1 (en) 2011-08-19 2014-04-10 Synta Pharmaceuticals Corp. Combination cancer therapy of HSP90 inhibitor with antimetabolite
EP2959899B1 (en) 2011-08-23 2017-02-22 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
HK1200330A1 (en) 2011-09-23 2015-08-07 细胞基因公司 Romidepsin and 5 - azacitidine for use in treating lymphoma
CA2849903A1 (en) 2011-09-26 2013-04-04 Celgene Corporation Combination therapy for chemoresistant cancers
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US9610370B2 (en) 2011-10-07 2017-04-04 University Of Virginia Patent Foundation Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
WO2013055985A1 (en) 2011-10-12 2013-04-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
CN104066730B (zh) 2011-10-14 2017-03-08 埃姆比特生物科学公司 杂环化合物及其作为iii型受体酪氨酸激酶调节剂的用途
AU2012318239B2 (en) 2011-11-01 2015-07-09 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
AU2012324012A1 (en) 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
US8592445B2 (en) 2011-12-19 2013-11-26 Map Pharmaceuticals, Inc. Iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
SI2800578T1 (sl) 2012-01-05 2019-03-29 Boston Medical Center Corporation Signalizacija slit-robo za diagnosticiranje in zdravljenje ledvične bolezni
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
US9085551B2 (en) 2012-02-21 2015-07-21 Celgene Corporation Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
ES2779698T3 (es) 2012-03-19 2020-08-18 Brigham & Womens Hospital Inc Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2830616A1 (en) 2012-03-27 2015-02-04 Incuron LLC Curaxins for use in treating breast cancer and method for identifying patients likely to respond
WO2013148857A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
AU2013243381A1 (en) 2012-04-04 2014-10-09 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate Hsp90 activity
BR112014024848A2 (pt) 2012-04-04 2017-07-11 Halozyme Inc terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
NZ631539A (en) 2012-04-17 2016-10-28 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2844250B1 (en) 2012-05-01 2017-11-08 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
JP6114382B2 (ja) 2012-05-11 2017-04-12 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのベンゾモルファン化合物
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
AU2013274101B2 (en) 2012-06-15 2017-09-07 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
JP6318152B2 (ja) 2012-06-29 2018-04-25 セルジーン コーポレイション セレブロン関連タンパク質を利用して薬物効能を決定する方法
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
EA029085B1 (ru) 2012-08-09 2018-02-28 Селджин Корпорейшн Способ лечения иммуноопосредуемых и воспалительных заболеваний с помощью 3-[4-(4-морфолин-4-илметилбензилокси)-1-оксо-1,3-дигидроизоиндол-2-ил]пиперидин-2,6-диона
JP6419072B2 (ja) 2012-08-09 2018-11-07 セルジーン コーポレイション （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの塩及び固体形態、並びにそれらを含有する組成物及び使用方法
EP3949968A1 (en) 2012-08-09 2022-02-09 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014028610A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2014030053A1 (en) 2012-08-20 2014-02-27 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
BR112015004959A2 (pt) 2012-09-07 2017-07-04 Axikin Pharmaceuticals Inc composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
AU2013312188A1 (en) 2012-09-10 2015-03-26 Celgene Corporation Methods for the treatment of locally advanced breast cancer
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
HK1207647A1 (en) 2012-10-08 2016-02-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for hcv infection
CN104853776B (zh) 2012-10-12 2021-04-09 布里格姆及妇女医院股份有限公司 免疫应答的增强
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
WO2014074846A1 (en) 2012-11-09 2014-05-15 Celgene Corporation Methods for the treatment of bone loss
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
EP3447046A1 (en) 2012-11-30 2019-02-27 Novomedix, LLC Substituted biaryl sulfonamides and the use thereof
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
ES2621305T3 (es) 2012-12-14 2017-07-03 Purdue Pharma Lp Morfinanos espirocíclicos y su uso
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014100354A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
EP2941430B1 (en) 2012-12-28 2017-04-26 Purdue Pharma LP 7,8-cyclicmorphinan analogs
TW201441199A (zh) 2012-12-28 2014-11-01 Purdue Pharma Lp 經取代之嗎啡喃類及其用途
CA2896871A1 (en) 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
CN110051638B (zh) 2013-01-05 2022-02-01 安济药业(美国)有限责任公司 包含双胍的延迟释放组合物
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014118618A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US10583103B2 (en) 2013-03-13 2020-03-10 University Of Cincinnati Method of treating heart failure with preserved ejection fraction with probenecid
MX384501B (es) 2013-03-14 2025-03-14 Amgen Europe Gmbh Tratamiento de artritis psoriasica usando apremilast.
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
CN107056838A (zh) 2013-03-15 2017-08-18 加利福尼亚大学董事会 无环核苷膦酸二酯
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US9839632B2 (en) 2013-04-02 2017-12-12 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
US20160220640A1 (en) 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
CN105705152B (zh) 2013-06-14 2021-07-09 阿卡玛拉疗法有限公司 基于脂质的铂化合物和纳米粒子
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2014203140A1 (en) 2013-06-22 2014-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
EP3013344B1 (en) 2013-06-28 2018-10-24 Purdue Pharma L.P. Opioid antagonists for use in the treatment of an opioid analgesic-induced arrhythmia
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
CA2922361C (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
SG11201601341QA (en) 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
ES2729642T3 (es) 2013-09-24 2019-11-05 Purdue Pharma Lp Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015070203A1 (en) 2013-11-11 2015-05-14 Naturex-Dbs Llc Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CA3151082A1 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
JP6599334B2 (ja) 2013-12-20 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
US9988392B2 (en) 2013-12-26 2018-06-05 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
EP3666273A3 (en) 2014-01-15 2020-10-28 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2733552T3 (es) 2014-01-24 2019-11-29 Celgene Corp Procedimientos para el tratamiento de la obesidad mediante apremilast
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015138420A1 (en) 2014-03-10 2015-09-17 Kadmon Corporation, Llc Treatment of brain and central nervous system tumors
US10472324B2 (en) 2014-03-18 2019-11-12 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
AU2015231202B9 (en) 2014-03-20 2019-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
CN106661027B (zh) 2014-03-20 2019-12-24 卡佩拉医疗公司 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
EP3122337A4 (en) 2014-03-26 2017-11-08 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release coated reservoir solid dosage form
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
AU2015243437B2 (en) 2014-04-09 2019-08-29 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins useful for the treatment of pain
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CA2983796A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
CN106573872B (zh) 2014-05-19 2021-07-20 东北大学 5-羟色胺受体靶向化合物和方法
WO2015176780A1 (en) 2014-05-23 2015-11-26 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
JP2017516779A (ja) 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
JP2017518307A (ja) 2014-06-02 2017-07-06 チルドレンズ メディカル センター コーポレーション 免疫調節のための方法および組成物
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
SMT201900142T1 (it) 2014-06-19 2019-05-10 Ariad Pharma Inc Composti eteroarilici per inibizione di chinasi
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3174550B1 (en) 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
FI3182996T3 (fi) 2014-08-22 2023-03-28 Celgene Corp Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
CN107106704A (zh) 2014-08-29 2017-08-29 儿童医疗中心有限公司 用于治疗癌症的方法和组合物
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
KR102589658B1 (ko) 2014-09-15 2023-10-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뉴클레오타이드 유사체
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN111888368B (zh) 2014-10-21 2024-02-02 武田药品工业株式会社 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR20170102223A (ko) 2014-11-07 2017-09-08 시그모이드 파마 리미티드 사이클로스포린을 포함하는 조성물
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EA201791346A1 (ru) 2014-12-16 2018-01-31 Селджин Корпорейшн ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
CN107645957A (zh) 2015-02-09 2018-01-30 辛塔制药公司 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
CN114366802A (zh) 2015-04-22 2022-04-19 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108368147A (zh) 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
JP6919099B2 (ja) 2015-06-23 2021-08-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
EP3313818B1 (en) 2015-06-26 2023-11-08 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
AU2016298826A1 (en) 2015-07-28 2018-02-15 Vyome Therapeutics Limited Antibacterial therapeutics and prophylactics
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US10704035B2 (en) 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
RU2022102624A (ru) 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US20180312534A1 (en) 2015-10-16 2018-11-01 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
HRP20240304T1 (hr) 2015-10-30 2024-05-10 Neurocrine Biosciences, Inc. Soli valbenazin dihidroklorida i njihovi polimorfi
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN121181546A (zh) 2015-12-02 2025-12-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
CA3013554A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Targeted therapeutic agents and uses thereof
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
CA3016849A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
KR102498741B1 (ko) 2016-04-29 2023-02-10 에프지에이치 바이오테크 인코포레이티드 질환 치료용 이-치환된 피라졸 화합물
EP3452473A1 (en) 2016-05-04 2019-03-13 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
DK3484475T3 (da) 2016-07-18 2023-11-27 Pharmena S A 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
HUE070203T2 (hu) 2016-07-29 2025-05-28 Sumitomo Pharma America Inc Vegyületek és készítmények és alkalmazásaik
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
EP3510027B1 (en) 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US10918628B2 (en) 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
WO2018075996A1 (en) 2016-10-21 2018-04-26 Cedars-Sinai Medical Center Simvastatin and chemotherapeutic conjugates with a heptamethine carbocyanine dye resensitize human tumors to hormonal antagonists and chemotherapy
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2018140671A1 (en) 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
EA201991618A1 (ru) 2017-02-06 2020-01-30 Сперо Терапьютикс, Инк. Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3542800B1 (en) 2017-02-21 2022-06-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3585410B9 (en) 2017-02-27 2023-10-04 Shattuck Labs, Inc. Vsig8-based chimeric proteins
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP7777915B2 (ja) 2017-03-27 2025-12-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置する組成物及び方法
CN110914276A (zh) 2017-03-29 2020-03-24 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
KR20200012833A (ko) 2017-03-29 2020-02-05 사이트원 테라퓨틱스, 인코포레이티드 통증 치료용 11,13-개질된 색시톡신
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
PL3624796T3 (pl) 2017-05-19 2025-06-30 Nflection Therapeutics, Inc. Związki pirolopirydyno-anilinowe do leczenia zaburzeń skórnych
DK3624795T3 (da) 2017-05-19 2022-05-23 Nflection Therapeutics Inc Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
EP3630079A4 (en) 2017-05-31 2021-02-24 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASE (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSED LARGE B-CELL LYMPHOMA
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2018313738B2 (en) 2017-08-07 2024-07-04 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3076920A1 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019097080A1 (en) 2017-11-20 2019-05-23 Kiakos Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CA3085593A1 (en) 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TWI823890B (zh) 2018-01-10 2023-12-01 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
KR20200103045A (ko) 2018-01-24 2020-09-01 퍼듀 퍼머 엘피 수면 장애 치료 및 예방
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN112119092A (zh) 2018-02-12 2020-12-22 无糖尿病公司 改进的拮抗性抗人cd40单克隆抗体
US12208071B2 (en) 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
US20210008030A1 (en) 2018-02-16 2021-01-14 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
MX2020008680A (es) 2018-02-21 2020-09-25 Ai Therapeutics Inc Terapia de combinacion con apilimod y agentes glutamatergicos.
WO2019182683A1 (en) 2018-03-22 2019-09-26 The Children's Medical Center Corporation Methods and compositions relating to lung repair
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN108836948B (zh) * 2018-06-11 2024-04-12 宁波西敦医药包衣科技有限公司 一种利用包衣技术实现营养素可控制释放的产品
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
JOP20200336A1 (ar) 2018-08-15 2020-12-22 Neurocrine Biosciences Inc طرق إعطاء مثبطات vmat2 معينة
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MX2021002292A (es) 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US12162886B2 (en) 2018-10-03 2024-12-10 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
AU2019372141A1 (en) 2018-11-01 2021-05-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
EP3876966A4 (en) 2018-11-09 2022-07-27 The Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF THE DEVELOPMENT OF FOOD ALLERGIES
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11572344B2 (en) 2018-11-20 2023-02-07 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
AU2019383310B2 (en) 2018-11-20 2025-08-14 H. Lee Moffitt Cancer Center & Research Institute Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
EP3883554A4 (en) 2018-11-20 2022-11-23 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
SG11202106599WA (en) 2018-12-21 2021-07-29 Kura Oncology Inc Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP3921038A1 (en) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
CA3129243A1 (en) 2019-02-07 2020-08-13 Alsatech, Inc. Polyvalent derivatives of emoxypine
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3935042B1 (en) 2019-03-07 2024-08-28 NOBO Medicine Inc. Caspase inhibitors and methods of use thereof
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
EP3941900A1 (en) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
JP7641232B2 (ja) 2019-03-29 2025-03-06 クラ オンコロジー， インコーポレイテッド ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3946261A1 (en) 2019-04-03 2022-02-09 President And Fellows Of Harvard College Ionic liquids for drug delivery
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
US12310955B2 (en) 2019-06-03 2025-05-27 Irimajiri Therapeutics Inc. Cyclic amide compounds for rabies treatment and method thereof
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
GB201909137D0 (en) * 2019-06-25 2019-08-07 Univ Aston Mesoporous polymeric particulate material
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CN118903087A (zh) 2019-07-26 2024-11-08 埃斯佩尔维塔治疗股份有限公司 可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
CN114615984B (zh) 2019-10-01 2025-02-07 分子皮肤治疗公司 作为klk5/7双重抑制剂的苯并噁嗪酮化合物
IL292836A (en) 2019-11-12 2022-07-01 Actym Therapeutics Inc Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
EP4061338A1 (en) 2019-11-22 2022-09-28 President And Fellows Of Harvard College Ionic liquids for drug delivery
CN115315260A (zh) 2019-12-02 2022-11-08 新基公司 治疗癌症的疗法
WO2021183318A2 (en) 2020-03-09 2021-09-16 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CN115996751A (zh) 2020-04-28 2023-04-21 哈佛大学校长及研究员协会 与离子液体佐剂有关的方法和组合物
WO2021226033A1 (en) 2020-05-07 2021-11-11 President And Fellows Of Harvard College Hyaluronic acid drug conjugates
WO2021242794A2 (en) 2020-05-29 2021-12-02 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20230102840A1 (en) 2020-06-23 2023-03-30 President And Fellows Of Harvard College Compositions and methods relating to combinatorial hyaluronic acid conjugates
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
CA3184852A1 (en) 2020-07-10 2022-01-13 Lida Katsimpardi Use of gdf11 to diagnose and treat anxiety and depression
MX2023001782A (es) 2020-08-12 2023-05-22 Actym Therapeutics Inc Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
WO2022036297A1 (en) 2020-08-14 2022-02-17 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
TW202233173A (zh) 2020-10-30 2022-09-01 愛爾蘭商Ｄｓ生物製藥有限公司 包括１５－ＨＥＴｒＥ之醫藥組合物及其使用方法
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022187573A1 (en) 2021-03-05 2022-09-09 President And Fellows Of Harvard College Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189010A1 (en) 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN117642396A (zh) 2021-03-10 2024-03-01 戴斯分子Sv有限公司 αVβ6和αVβ1整联蛋白抑制剂及其用途
IL319926A (en) 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022246298A1 (en) 2021-05-21 2022-11-24 Whiteside Garth Methods of treating interstitial cystitis/bladder pain syndrome
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
JP2024530927A (ja) 2021-08-05 2024-08-27 ブリストル－マイヤーズ スクイブ カンパニー Ｈｅｒ２阻害剤として使用するための三環系縮合ピリミジン化合物
WO2023034504A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
US20230083717A1 (en) 2021-09-01 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for promoting adipocyte beiging
EP4396330A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin
EP4396380A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
US20230077584A1 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating enteroendocrine cells
US20240361301A1 (en) 2021-09-09 2024-10-31 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
US20240374592A1 (en) 2021-09-14 2024-11-14 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
WO2023069770A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
TW202327590A (zh) 2021-11-30 2023-07-16 美商庫拉腫瘤技術股份有限公司 大環化合物及組合物以及其製備及使用方法
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
JP2025513822A (ja) 2022-04-15 2025-04-30 セルジーン コーポレーション 薬物に対するリンパ腫の応答性を予測する方法及びリンパ腫を治療する方法
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのｎａｖ１．８の二環式複素環アミド阻害剤
CA3257018A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. METHOD FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
EP4531879A1 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions of secretory and/or catalytic cells and methods using the same
CA3267079A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DOUBLE CK1α/GSPT1 DEGRADATION COMPOUNDS
WO2024071371A1 (ja) 2022-09-30 2024-04-04 ユビエンス株式会社 複素環式化合物
EP4593826A1 (en) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
AU2023365200A1 (en) 2022-10-18 2025-05-15 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
WO2024091863A1 (en) 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024097940A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Therapy for the treatment of cancer
EP4626864A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
AU2024245246A1 (en) 2023-03-27 2025-10-30 Tonix Pharma Limited (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
US20240368596A1 (en) 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025078239A1 (en) 2023-10-09 2025-04-17 Givaudan Sa Compositions
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder
WO2025085878A1 (en) 2023-10-20 2025-04-24 Altay Therapeutics, Inc. N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
WO2025102082A1 (en) 2023-11-10 2025-05-15 Altay Therapeutics, Inc. Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025120113A1 (en) 2023-12-08 2025-06-12 Celgene Corporation Therapy for the treatment of multiple myeloma
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025221809A1 (en) 2024-04-16 2025-10-23 Eluciderm Inc. 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
WO2025227129A2 (en) 2024-04-25 2025-10-30 Starrock Pharma Llc Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2025240895A1 (en) 2024-05-17 2025-11-20 Siteone Therapeutics, Inc. SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA494130A (en) * 1953-06-30 Western Electric Company, Incorporated Power and impedance monitor
CA873815A (en) * 1971-06-22 G. Mason Stanley Encapsulated hydrophilic compositions and methods of making them
NL6603111A (cg-RX-API-DMAC7.html) * 1956-11-24 1966-09-20
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3115441A (en) * 1962-06-06 1963-12-24 Victor M Hermelin Timed release pharmaceutical preparations and method of making the same
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
US3341416A (en) * 1963-12-11 1967-09-12 Ncr Co Encapsulation of aspirin in ethylcellulose and its product
GB1056259A (en) * 1964-11-30 1967-01-25 Lyons & Co Ltd J Flavour powders
US3594326A (en) * 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3460972A (en) * 1965-09-29 1969-08-12 Battelle Development Corp Liquid encapsulation
US3488418A (en) * 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
GB1205770A (en) * 1966-07-26 1970-09-16 Nat Patent Dev Corp Body implants
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3657144A (en) * 1967-06-05 1972-04-18 Ncr Co Encapsulation process
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
US3732172A (en) * 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3576759A (en) * 1968-04-12 1971-04-27 Ncr Co Process for en masse production of spherules by desiccation
JPS5212150B1 (cg-RX-API-DMAC7.html) * 1968-06-04 1977-04-05
US3639306A (en) * 1968-08-08 1972-02-01 Amicon Corp Encapsulating particles and process for making same
US3539465A (en) * 1968-10-08 1970-11-10 Ncr Co Encapsulation of hydrophilic liquid-in-oil emulsions
US3634586A (en) * 1968-12-04 1972-01-11 Bristol Myers Co Stable aqueous suspensions of ampicillin
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3567650A (en) * 1969-02-14 1971-03-02 Ncr Co Method of making microscopic capsules
US3642978A (en) * 1969-03-05 1972-02-15 Mochida Pharm Co Ltd Process for producing stable cytochrome c preparation
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
GB1287431A (en) * 1969-04-16 1972-08-31 Aspro Nicholas Ltd Improvements in pharmaceutical formulations
US3703576A (en) * 1969-08-08 1972-11-21 Fuji Photo Film Co Ltd Method of producing micro-capsules enclosing acetylsalicylic acid therein
US3629392A (en) * 1969-08-15 1971-12-21 Gilbert S Banker Entrapment compositions and processes
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
CA923384A (en) * 1970-02-03 1973-03-27 Abe Jinnosuke Process for preparing a micro capsule
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US3821422A (en) * 1971-03-04 1974-06-28 Merck & Co Inc Devil's food cake and other alkaline bakery goods
JPS5214234B2 (cg-RX-API-DMAC7.html) * 1971-07-30 1977-04-20
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
JPS528795B2 (cg-RX-API-DMAC7.html) * 1971-12-30 1977-03-11
JPS523342B2 (cg-RX-API-DMAC7.html) * 1972-01-26 1977-01-27
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1403584A (en) * 1972-05-19 1975-08-28 Beecham Group Ltd Control medicaments
JPS5438164B2 (cg-RX-API-DMAC7.html) * 1972-05-29 1979-11-19
BE791458A (fr) * 1972-07-31 1973-05-16 Merck & Co Inc Produit microencapsule
DE2237503A1 (de) * 1972-07-31 1974-10-03 Basf Ag Verfahren zur herstellung von mikrokapseln
JPS4962623A (cg-RX-API-DMAC7.html) * 1972-10-18 1974-06-18
JPS4993522A (cg-RX-API-DMAC7.html) * 1973-01-12 1974-09-05
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
FR2236483B1 (cg-RX-API-DMAC7.html) * 1973-07-12 1976-11-12 Choay Sa
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS5094112A (cg-RX-API-DMAC7.html) * 1973-12-06 1975-07-26
US3962468A (en) * 1974-03-07 1976-06-08 General Foods Corporation Spray-dried L-aspartic acid derivatives
US4118336A (en) * 1974-03-25 1978-10-03 Toyo Jozo Company, Ltd. Novel cellulose microcapsules and preparation thereof
DE2452975C2 (de) * 1974-11-08 1982-09-16 Dr. C. Otto & Comp. Gmbh, 4630 Bochum Füllwagen für Verkokungsöfen
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4123381A (en) * 1975-02-20 1978-10-31 Toyo Jozo Company, Ltd. Process for producing cellulose microcapsules, and resulting cellulose microcapsules
US4011312A (en) * 1975-06-25 1977-03-08 American Home Products Corporation Prolonged release drug form for the treatment of bovine mastitis
JPS523653A (en) * 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4324683A (en) * 1975-08-20 1982-04-13 Damon Corporation Encapsulation of labile biological material
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
PT66201B (fr) * 1976-02-23 1978-11-07 Corvi Mora E Procede et composition pour la therapeutique des maladies circulatoires cerebrales
CH627449A5 (de) * 1977-03-25 1982-01-15 Hoffmann La Roche Verfahren zur herstellung von mikrokristallinem vitamin a-acetat, sowie von trockenen, frei-fliessenden praeparaten, in welchen vitamin a-acetat in mikrokristalliner form vorliegt.
DE2856901D2 (de) * 1977-06-07 1980-11-13 Garching Instrumente Form of implant medicament and preparation process
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
AT355053B (de) * 1978-03-03 1980-02-11 Koreska Gmbh W Mikrokapseln fuer aufzeichnungsmaterialien und verfahren zu deren herstellung
DE2809659A1 (de) * 1978-03-07 1979-09-13 Kores Holding Zug Ag Mikrokapseln fuer aufzeichnungsmaterialien und verfahren zu deren herstellung
US4182778A (en) * 1978-05-17 1980-01-08 General Foods Corporation Encapsulation of vitamin and mineral nutrients
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
US4489055A (en) * 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
JPS5524938A (en) * 1978-08-10 1980-02-22 Nippon Kokan Kk <Nkk> Manufacture of galvanized cold rolled steel plate excellent in deep drawability
US4205060A (en) * 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4368197A (en) * 1979-02-21 1983-01-11 Research Corporation Zinc aminophylline and its use in the treatment of bronchospasms
US4201822A (en) * 1979-06-13 1980-05-06 The United States Of America As Represented By The Secretary Of The Army Novel fabric containing microcapsules of chemical decontaminants encapsulated within semipermeable polymers
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
JPS5569509A (en) * 1979-11-30 1980-05-26 Mcleod Patrick Biologically decomposable particle
US4280995A (en) * 1979-12-31 1981-07-28 Pharmaceutical Associates, Inc. Oral suspension of phenytoin
JPS56152739A (en) * 1980-04-25 1981-11-26 Tanabe Seiyaku Co Ltd Production of microcapsule
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
FR2485370A1 (fr) * 1980-06-30 1981-12-31 Commissariat Energie Atomique Support inerte en copolymere reticule, son procede de preparation et son utilisation pour la realisation de medicaments retard
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS58401A (ja) * 1981-06-26 1983-01-05 Yokohama Rubber Co Ltd:The 充填タイヤ
EP0083372B1 (en) * 1981-07-15 1988-05-18 Key Pharmaceuticals, Inc. Sustained release theophyline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4452821A (en) * 1981-12-18 1984-06-05 Gerhard Gergely Confectionery product, particularly chewing gum, and process for its manufacture
DE3218150C2 (de) * 1982-05-14 1986-09-25 Akzo Gmbh, 5600 Wuppertal Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4497832A (en) * 1983-04-18 1985-02-05 Warner-Lambert Company Chewing gum composition having enhanced flavor-sweetness
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4590825A (en) 1983-05-06 1986-05-27 John Vaughn High torque fastener and driving tool
GB2141023B (en) * 1983-06-06 1986-09-03 Robins Co Inc A H Delayed release formulations
US4647459A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US4632822A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
SE8404808L (sv) * 1983-10-03 1985-04-04 Avner Rotman Mikrokapslat lekemedel i sot matris
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
JPS6110A (ja) * 1984-06-08 1986-01-06 Sekisui Chem Co Ltd 貼付製剤の製造方法
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
仲井 花野著「新製剤学」第１版（１９８２−１１−２５）南山堂 Ｐ．２５９〜２６３

Also Published As

Publication number Publication date
DE3538429A1 (de) 1986-04-30
SE8505099L (sv) 1986-05-01
FR2572282A1 (fr) 1986-05-02
CH669728A5 (cg-RX-API-DMAC7.html) 1989-04-14
GB2166651A (en) 1986-05-14
US4952402A (en) 1990-08-28
GB2166651B (en) 1988-11-16
NL8502951A (nl) 1986-05-16
BE903540A (fr) 1986-02-17
DK175329B1 (da) 2004-08-23
DK495585A (da) 1986-05-01
NL193582C (nl) 2000-03-02
HK44091A (en) 1991-06-14
NL193582B (nl) 1999-11-01
CA1268051A (en) 1990-04-24
AU579415B2 (en) 1988-11-24
IT8567913A0 (it) 1985-10-29
AU4916185A (en) 1986-05-08
IE58110B1 (en) 1993-07-14
IT1185831B (it) 1987-11-18
ZA858300B (en) 1986-07-30
FR2572282B1 (fr) 1989-03-31
SE8505099D0 (sv) 1985-10-29
GB8526591D0 (en) 1985-12-04
US5354556A (en) 1994-10-11
DE3538429C2 (de) 1996-10-24
BE903541Q (fr) 1986-02-17
DK495585D0 (da) 1985-10-29
JPS61109711A (ja) 1986-05-28
US4940588A (en) 1990-07-10

Similar Documents

Publication Publication Date Title
JP2820239B2 (ja) 制御放出パウダー及びその製法
CA2169376C (en) Procedure for encapsulating nsaids
US6214386B1 (en) Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
JP3233638B2 (ja) 凍結乾燥された薬投与形状物の製造方法
US5494681A (en) Tastemasked pharmaceutical materials
DE19856432A1 (de) Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
JPS63166838A (ja) 経口投与用液体製剤
EP0851758A1 (en) Pharmaceutical formulation
US4892740A (en) Orally administrable pharmaceutical preparation of improved flavoring characteristics
DE602005003343T2 (de) Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
JP2000510488A (ja) 改良投薬ユニット
WO2000024379A1 (fr) Procede de production de fines particules spheriques contenant un medicament
DE60031307T2 (de) Mikroverkapselte kräuter formulierungen mit gesteuerter freigabe
JP2000500477A (ja) 即時放出型の薬学的組成物
JP3221891B2 (ja) 咀嚼可能な製薬錠剤調製のための回転造粒及び味覚遮蔽被覆加工
US20020076444A1 (en) Novel method for obtaining microspheres and resulting products
KR20040018440A (ko) 지용성 물질을 포함하는 과립형 물질 및 제조방법
IE902829A1 (en) Microencapsulated taste-masked water-insoluble nsaid drug¹materials
KR20110003357A (ko) 수 현탁성을 향상시킨 세립제
EP0948321B1 (de) Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds
EP0540813B1 (en) Sustained release formulations of acetazolamide
RU2842481C1 (ru) Фармацевтические композиции, содержащие покрытый api
DE19749897C1 (de) Zubereitung in Form eines Lipid-Hilfsstoff-Compounds und/oder eines Lipid-Wirkstoff-Compounds und Verfahren zu dessen Herstellung sowie dessen Verwendung zur Herstellung von Tabletten und/oder anderen größeren Matrixeinheiten
Mani Microencapsulation of a hydrophilic drug into a hydrophobic matrix using a salting-out procedure and development of tableted microspheres
Borin New product formulations and pharmacokinetics of acetaminophen

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term